Talniflumate | CAS#66898-62-2 | GCNT3 Inhibitor

MedKoo Cat#: 526070 | Name: Talniflumate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Talniflumate is a novel potent and selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2b-1,6 N-acetylglucosaminyltrans-ferase).

Chemical Structure

Talniflumate

CAS#66898-62-2

Theoretical Analysis

MedKoo Cat#: 526070

Name: Talniflumate

CAS#: 66898-62-2

Chemical Formula: C21H13F3N2O4

Exact Mass: 414.0827

Molecular Weight: 414.34

Elemental Analysis: C, 60.88; H, 3.16; F, 13.76; N, 6.76; O, 15.45

Price and Availability

Size	Price	Availability	Quantity
200mg	USD 250.00
500mg	USD 450.00
1g	USD 850.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Talniflumate

IUPAC/Chemical Name

2-[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid 1,3-dihydro-3-oxo-1-isobenzofuranyl ester

InChi Key

ANMLJLFWUCQGKZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)

SMILES Code

O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)OC3OC(C4=C3C=CC=C4)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 414.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Özay B, Tükel EY, Ayna Duran G, Kiraz Y. Identification of potential inhibitors for drug resistance in acute lymphoblastic leukemia through differentially expressed gene analysis and in silico screening. Anal Biochem. 2024 Nov;694:115619. doi: 10.1016/j.ab.2024.115619. Epub 2024 Jul 16. PMID: 39025197. 2: Joshi P, Pandey P, Rawat S, Chandra S. Repurposing of Drug Bank Compounds against Plasmodium falciparum Dihydroorotate Dehydrogenase as novel anti malarial drug candidates by Computational approaches. In Silico Pharmacol. 2024 Jul 6;12(2):60. doi: 10.1007/s40203-024-00232-1. PMID: 38978708; PMCID: PMC11227489. 3: Agostini A, Guerriero I, Piro G, Quero G, Roberto L, Esposito A, Caggiano A, Priori L, Scaglione G, De Sanctis F, Sistigu A, Musella M, Larghi A, Rizzatti G, Lucchetti D, Alfieri S, Sgambato A, Bria E, Bizzozero L, Arena S, Ugel S, Corbo V, Tortora G, Carbone C. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. J Transl Med. 2023 Nov 23;21(1):843. doi: 10.1186/s12967-023-04733-z. PMID: 37996891; PMCID: PMC10668479. 4: Jeong J, Han H, Ro DH, Han HS, Won S. Development of Prediction Model Using Machine-Learning Algorithms for Nonsteroidal Anti-inflammatory Drug-Induced Gastric Ulcer in Osteoarthritis Patients: Retrospective Cohort Study of a Nationwide South Korean Cohort. Clin Orthop Surg. 2023 Aug;15(4):678-689. doi: 10.4055/cios22240. Epub 2023 May 26. PMID: 37529187; PMCID: PMC10375806. 5: Liu Y, Liu T, Zhou Y, Li W, Wang M, Song N, Zhang W, Jiang J, Yuan S, Ding J, Hu G, Lu M. Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease. Acta Pharm Sin B. 2023 Feb;13(2):662-677. doi: 10.1016/j.apsb.2022.07.021. Epub 2022 Aug 3. PMID: 36873178; PMCID: PMC9978855. 6: He M, Wang Y, Zhang X, Zhang L. Exploration of the potential neuroprotective compounds targeting GluN1-GluN2B NMDA receptors. J Biomol Struct Dyn. 2023 Dec;41(20):10900-10908. doi: 10.1080/07391102.2022.2159527. Epub 2023 Jan 2. PMID: 36591642. 7: Sisakht M, Solhjoo A, Mahmoodzadeh A, Fathalipour M, Kabiri M, Sakhteman A. Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19. Comput Biol Med. 2021 Sep;136:104686. doi: 10.1016/j.compbiomed.2021.104686. Epub 2021 Jul 29. PMID: 34340125; PMCID: PMC8319042. 8: Gupta R, Leon F, Thompson CM, Nimmakayala R, Karmakar S, Nallasamy P, Chugh S, Prajapati DR, Rachagani S, Kumar S, Ponnusamy MP. Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis. Br J Cancer. 2020 May;122(11):1661-1672. doi: 10.1038/s41416-020-0772-3. Epub 2020 Mar 19. Erratum in: Br J Cancer. 2020 May;122(11):1726. doi: 10.1038/s41416-020-0842-6. PMID: 32203219; PMCID: PMC7251111. 9: Jin LH, Kim BH, Lee JH, Lee K, Kwack K, Yim SV. Screening study for genetic polymorphisms affecting pharmacokinetics of talniflumate. Transl Clin Pharmacol. 2017 Dec;25(4):166-172. doi: 10.12793/tcp.2017.25.4.166. Epub 2017 Dec 20. PMID: 32095470; PMCID: PMC7033407. 10: Kim Y, Yim S, Kim BH, Lee S. Pharmacokinetic comparison of two formulations of talniflumate 370 mg tablets in healthy Korean volunteers . Int J Clin Pharmacol Ther. 2017 Jan;55(1):102-108. doi: 10.5414/CP202707. PMID: 27879193. 11: Rao CV, Janakiram NB, Madka V, Kumar G, Scott EJ, Pathuri G, Bryant T, Kutche H, Zhang Y, Biddick L, Gali H, Zhao YD, Lightfoot S, Mohammed A. Small- Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. Cancer Res. 2016 Apr 1;76(7):1965-74. doi: 10.1158/0008-5472.CAN-15-2820. Epub 2016 Feb 15. PMID: 26880801. 12: Kang HA, Lee SM, Park C, Kim DS. Prevalence and predictors of non-steroidal anti-inflammatory drug/analgesic therapeutic duplication in the South Korean ambulatory care setting. Eur J Clin Pharmacol. 2016 Jan;72(1):109-16. doi: 10.1007/s00228-015-1958-0. PMID: 26490355. 13: Kim E, Kang W. Contribution of pH to systemic exposure of niflumic acid following oral administration of talniflumate. Eur J Clin Pharmacol. 2011 Apr;67(4):425-428. doi: 10.1007/s00228-010-0980-5. Epub 2011 Feb 17. PMID: 21327911. 14: Kang W, Kim K. Determination of talniflumate and niflumic acid in human plasma by liquid chromatography-tandem mass spectrometry. Anal Sci. 2009 Apr;25(4):571-4. doi: 10.2116/analsci.25.571. PMID: 19359802. 15: Park EJ, Na DH, Shin YH, Lee KC. Liquid chromatography-mass spectrometric method for the sensitive determination of niflumic acid in human plasma and its application to pharmacokinetic study of talniflumate tablet. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Dec 15;876(2):159-62. doi: 10.1016/j.jchromb.2008.10.010. Epub 2008 Oct 14. PMID: 19010744. 16: Kang W, Kim K, Kim EY, Kwon KI, Bang JS, Yoon YR. Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate. Eur J Clin Pharmacol. 2008 Oct;64(10):1027-30. doi: 10.1007/s00228-008-0524-4. Epub 2008 Jul 8. PMID: 18607579. 17: Walker NM, Simpson JE, Levitt RC, Boyle KT, Clarke LL. Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome. J Pharmacol Exp Ther. 2006 Apr;317(1):275-83. doi: 10.1124/jpet.105.094847. Epub 2005 Dec 14. PMID: 16354791. 18: Jung YS, Kim MK, Um YJ, Park HS, Lee EW, Kang JW. The effects on postoperative oral surgery pain by varying NSAID administration times: comparison on effect of preemptive analgesia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Nov;100(5):559-63. doi: 10.1016/j.tripleo.2005.02.065. PMID: 16243240. 19: Lee HW, Won KJ, Cho SH, Ha YH, Park WS, Yim HT, Baek M, Rew JH, Yoon SH, Yim SV, Chung JH, Lee KT. Quantitation of niflumic acid in human plasma by high- performance liquid chromatography with ultraviolet absorbance detection and its application to a bioequivalence study of talniflumate tablets. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 25;821(2):215-20. doi: 10.1016/j.jchromb.2005.05.008. PMID: 15921965. 20: Jang DJ, Park JS, Ko HR, Jee JP, Kim JK, Kim ST, Kim CK. Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography. Biomed Chromatogr. 2005 Jan;19(1):32-5. doi: 10.1002/bmc.412. PMID: 15470687.